Biology Reference
In-Depth Information
76. Alvarez R, Elbashir S, Borland T et al (2009) RNA interference-mediated silencing of the
respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents
Chemother 53(9):3952-3962
77. Behlke MA (2006) Progress towards in vivo use of siRNAs. Mol Ther 13(4):644-670
78. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA
delivery. Nat Rev Drug Discov 8(2):129-138
79. Illum L (1998) Chitosan and its use as a pharmaceutical excipient. Pharm Res 15(9):
1326-1331
80. Artursson P, Lindmark T, Davis SS, Illum L (1994) Effect of chitosan on the permeability of
monolayers of intestinal epithelial cells (caco-2). Pharm Res 11(9):1358-1361
81. Borchard G, Lueßen HL, de Boer AG, Verhoef JC, Lehr C-M, Junginger HE (1996) The
potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III:
effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J Control
Release 39(2-3):131-138
82. Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L (1997) Chitosan as a nasal
delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport
rates in human turbinates and volunteers. J Pharm Sci 86(4):509-513
83. Köping-Höggård M, Vårum KM, Issa M, Danielsen S, Christensen BE, Stokke BT, Artursson
P (2004) Improved chitosan-mediated gene delivery based on easily dissociated chitosan
polyplexes of highly defined chitosan oligomers. Gene Ther 11(19):1441-1452
84. Liu X, Howard KA, Dong M, Andersen MØ, Rahbek UL, Johnsen MG, Hansen OC,
Besenbacher F, Kjems J (2007) The influence of polymeric properties on chitosan/siRNA
nanoparticle formulation and gene silencing. Biomaterials 28(6):1280-1288
85. Köping-Höggård M, Tubulekas I, Guan H, Edwards K, Nilsson M, Vårum KM, Artursson P
(2001) Chitosan as a nonviral gene delivery system Structure-property relationships and
characteristics compared with polyethylenimine in vitro and after lung administration in vivo.
Gene Ther 8(14):1108-1121
86. Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, Illum L (2003) Nasal delivery of
chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces pro-
tective CTL responses in BALB/c mice. Vaccine 21(13-14):1478-1485
87. Robbins M, Judge A, MacLachlan I (2009) siRNA and innate immunity. Oligonucleotides
19(2):89-102
88. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP
(2009) Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic
in fl ammation. Nature 458(7242):1180-1184
89. Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N (2010) Orally deliv-
ered thioketal nanoparticles loaded with TNF-a-siRNA target inflammation and inhibit gene
expression in the intestines. Nat Mater 9(11):923-928
90. Kriegel C, Amiji M (2011) Oral TNF-[alpha] gene silencing using a polymeric microsphere-
based delivery system for the treatment of inflammatory bowel disease. J Control Release
150(1):77-86
91. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M (2008) Systemic leukocyte-directed
siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319(5863):627-630
92. Zhang Y, Cristofaro P, Silbermann R et al (2006) Engineering mucosal RNA interference
in vivo. Mol Ther 14(3):336-342
93. Larson SD, Jackson LN, Chen LA, Rychahou PG, Evers BM (2007) Effectiveness of siRNA
uptake in target tissues by various delivery methods. Surgery 142(2):262-269
94. Palliser D, Chowdhury D, Wang Q-Y, Lee SJ, Bronson RT, Knipe DM, Lieberman J (2006)
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection.
Nature 439(7072):89-94
95. Wu Y, Navarro F, Lal A, Basar E, Pandey RK, Manoharan M, Feng Y, Lee SJ, Lieberman J,
Palliser D (2009) Durable protection from herpes simplex virus-2 transmission following
intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe
5(1):84-94
Search WWH ::




Custom Search